Feedback

Browsing by H

Use an asterisk (*) for partial word searches (e.g. pemph*)

269 results found.

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
Ordering Recommendation:  

Secondary test to diagnose autoimmune disease after adrenal insufficiency confirmed.

11.
Ordering Recommendation:  

Not the test of choice for initial evaluation of vitamin D insufficiency. Vitamin D, 25-hydroxy (0080379) is preferred for diagnosis.

12.
Ordering Recommendation:  

Differential diagnosis of myositis in patients with or without statin exposure.

13.
Ordering Recommendation:  

Use to diagnose carcinoid tumors and monitor disease.

14.
Ordering Recommendation:  

Evaluate the ability of a patient to produce antibody to a protein conjugated bacterial (H. influenza) vaccine to rule out antibody deficiency.

15.
16.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

17.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

18.
Ordering Recommendation:  

Use to detect hantavirus exposure.  Does not distinguish between Sin Nombre virus (cause of hantavirus pulmonary syndrome) and other hantaviruses (which cause hemorrhagic fever with renal syndrome).  For Sin Nombre virus-specific testing, contact your state health department.

19.
20.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

21.
22.
Ordering Recommendation:  

Diagnostic testing for nonsyndromic hearing loss.

23.
Ordering Recommendation:  

Diagnostic testing for GJB6-related nonsyndromic hearing loss. Carrier screening for GJB6-related nonsyndromic hearing loss.

24.
Ordering Recommendation:  

For individuals with nonsyndromic hearing loss and no identified mutations in GJB2 or GJB6.

25.
Ordering Recommendation:  

Not recommended for evaluation of general hearing loss.

26.
Ordering Recommendation:  

Useful in the assessment of recent exposure to arsenic, mercury, and lead. For chronic exposure or the determination of arsenic species, refer to Heavy Metals Panel 4, Urine with Reflex to Arsenic Fractionation (0020572). For occupational exposure, consider Lead, Industrial Exposure Panel, Adults (0025016) and/or Cadmium Exposure Panel - OSHA (0025013).

27.
Ordering Recommendation:  

Useful in the assessment of acute and chronic exposure to arsenic, mercury, and lead. The preferred test for the assessment of lead exposure is Lead, Blood (Venous) (0020098). For occupational exposure, consider Lead, Industrial Exposure Panel, Adults (0025016) and/or Cadmium Exposure Panel - OSHA (0025013).

28.
Ordering Recommendation:  

Useful in the assessment of acute and chronic exposure to arsenic, mercury, and lead. The preferred test for the assessment of lead exposure is Lead, Blood (Venous) (0020098). For occupational exposure, consider Lead, Industrial Exposure Panel, Adults (0025016) and/or Cadmium Exposure Panel - OSHA (0025013).

29.
Ordering Recommendation:  

Useful in the assessment of recent exposure to arsenic, cadmium, mercury, and lead. For chronic exposure or the determination of arsenic species, refer to Heavy Metals Panel 4, Urine with Reflex to Arsenic Fractionation (0020572). For occupational exposure, consider Lead, Industrial Exposure Panel, Adults (0025016) and/or Cadmium Exposure Panel - OSHA (0025013).

30.
Ordering Recommendation:  

Useful in the assessment of acute and chronic exposure to arsenic, cadmium, mercury, and lead. The preferred test for the assessment of lead exposure is Lead, Blood (Venous) (0020098). For occupational exposure, consider Lead, Industrial Exposure Panel, Adults (0025016) and/or Cadmium Exposure Panel - OSHA (0025013).

31.
Ordering Recommendation:  

Useful in the assessment of acute and chronic exposure to arsenic, cadmium, copper, mercury, lead, and zinc. The preferred test for the assessment of lead exposure is Lead, Blood (Venous) (0020098). For occupational exposure, consider Lead, Industrial Exposure Panel, Adults (0025016) and/or Cadmium Exposure Panel - OSHA (0025013).

32.
Ordering Recommendation:  

Use as a nonspecific screen for hemolysis due to drugs/toxins, enzyme deficiencies, thalassemias, and unstable hemoglobins.

33.
Ordering Recommendation:  

As an alternative to the H. pylori urea breath test, order this test to diagnose H. pylori.

34.
Ordering Recommendation:  

Use to diagnose H. pylori infection in adults (>17 years of age). For children and adolescents, refer to Helicobacter pylori Breath Test, Pediatric (2010925).

35.
Ordering Recommendation:  

Use to diagnose H. pylori infection in children and adolescents (3 to 17 years of age). For adults, refer to Helicobacter pylori Breath Test, Adult (2010476).

36.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

37.
Ordering Recommendation:  

Consider for diagnosis of H. pylori infection in children or for susceptibility testing in patients with treatment failure.

38.
39.
Ordering Recommendation:  

Confirm clinical diagnosis of hereditary hemochromatosis (HH) in an individual with biochemical findings of iron overload. Screen adult family members of individuals with known HH. Test reproductive partner of an individual with HH for carrier status. Not recommended for initial hemochromatosis testing.

40.
41.
Ordering Recommendation:  

Quantifies HbA2 and HbF in whole blood. Aids in the management of sickle cell disease and in the identification of beta thalassemia carriers.

42.
Ordering Recommendation:  

Use to diagnose and monitor diabetes mellitus. Monitor prediabetes.

43.
Ordering Recommendation:  

Optimal test for the initial and confirmatory diagnosis of any suspected hemoglobinopathy. A faculty hematopathologist personally directs and interprets each stage of testing to completion. A comprehensive report is provided. Do not use for the followup of an individual with a known diagnosis.

44.
Ordering Recommendation:  

Effective test for screening and follow up of individuals with known hemoglobinopathies. The optimal test for the initial diagnosis of a suspected hemoglobinopathy is Hemoglobin Evaluation Reflexive Cascade (2005792).

45.
Ordering Recommendation:  

Determines percentage of hemoglobin F. For complete hemoglobin evaluation, order Hemoglobin Evaluation with Reflex to Electrophoresis and/or RBC Solubility (0050610).

46.
Ordering Recommendation:  

Molecular confirmation of a suspected Hemoglobin (Hb) Lepore variant identified by Hb evaluation. Carrier screening for individuals with a family history of Hb Lepore.

47.
Ordering Recommendation:  

Determines presence of hemoglobin S.

48.
Ordering Recommendation:  

Effective test for secondary confirmation of hemoglobin (Hb) S. Not recommended for newborns <6 months due to high concentration of HbF. Confirm results with Hemoglobin Evaluation with Reflex to Electrophoresis and/or RBC Solubility (0050610). 

49.
Ordering Recommendation:  

• Identify increased concentration, which is indicative of acute intravascular destruction of erythrocytes.
• Not of clinical value in the diagnosis of chronic hemolytic disorders.

50.
Ordering Recommendation:  

• Identify increased concentration, which is indicative of acute intravascular destruction of erythrocytes.
• Not of clinical value in the diagnosis of chronic hemolytic disorders. 

51.
Ordering Recommendation:  

Use to confirm unstable nature of hemoglobins. Test cannot be used on infants <6 months of age due to physiologically elevated Hb F levels.

52.
Ordering Recommendation:  

Distinguish between hematuria and hemoglobinuria; hemoglobinuria in the absence of hematuria may indicate severe intravascular hemolysis.

53.
Ordering Recommendation:  

Identify causal F8 gene intron 22-A or intron 1 variant in individuals with established severe hemophilia A and determine carrier status of those with relatives with a known inversion of intron 1 or 22-A. The most comprehensive test for individuals with severe hemophilia A is Hemophilia A (F8) 2 Inversions with Reflex to Sequencing and Reflex to Deletion/Duplication​ (2001614). For mild to moderate hemophilia A, Hemophilia A (F8) Sequencing (2001747) is recommended.

54.
Ordering Recommendation:  

Detect causal F8 variant in individuals with established severe hemophilia A and determine carrier status in at-risk females with severely affected male relatives. For mild to moderate hemophilia A, Hemophilia A (F8) sequencing (2001747) is preferred.

55.
Ordering Recommendation:  

Prenatal testing for hemophilia A caused by a familial F8 gene intron 22-A or intron 1 inversion.

56.
Ordering Recommendation:  

This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred test is the sequencing and reflex to deletion/duplication test.

57.
Ordering Recommendation:  

Identify causal F8 variant in individuals with established mild to moderate hemophilia A and determine carrier status for those with a family history of mild to moderate hemophilia A. For severe hemophilia A,  Hemophilia A (F8) 2 Inversions with Reflex to Sequencing and Reflex to Deletion/Duplication (2001614) is recommended.

58.
Ordering Recommendation:  

This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.

59.
Ordering Recommendation:  

Acceptable test to confirm diagnosis or determine carrier status for F9 gene variants.

60.
Ordering Recommendation:  

Most comprehensive test to confirm diagnosis or determine carrier status for F9 gene mutations.

61.
62.
63.
64.
65.
66.
Ordering Recommendation:  

Not recommended to screen for heparin-PF4 antibodies that cause HIT; preferred test is Heparin-Induced Thrombocytopenia PF4 Ab, IgG (2012179).

67.
Ordering Recommendation:  

Recommended initial screening test for heparin-PF4 antibodies that cause HIT. Confirmation with Serotonin Release Assay (Heparin Dependent Platelet Antibody), Unfractionated Heparin (2005631) may be necessary based on clinical presentation.

68.
Ordering Recommendation:  

Gold standard reflex testing for confirming diagnosis of HIT. Serotonin Release Assay is performed for positive HIT Antibody, IgG.

69.
Ordering Recommendation:  

Initial screening for hepatobiliary inflammation. Panel includes albumin; ALP; AST; ALT; bilirubin, direct; protein, total; and bilirubin, total.

70.
Ordering Recommendation:  

This panel is not generally recommended. May be helpful when assessing immunity.

71.
Ordering Recommendation:  

Order to diagnose acute hepatitis A virus infection. For panel test that includes HAV IgM, HBV core antibody IgM, HBV surface antigen, and HCV antibody, refer to Hepatitis Panel, Acute with Reflex to HBsAg Confirmation (0020457).

72.
Ordering Recommendation:  

This panel is not recommended. To diagnose acute HAV infection, order Hepatitis A Virus Antibody, IgM (0020093) or Hepatitis Panel, Acute with Reflex to HBsAg Confirmation (0020457). To assess immunity, order Hepatitis A Virus Antibodies (Total) (0020591).

73.
Ordering Recommendation:  

Detect and quantify hepatitis B virus. Determine antiviral drug resistance.

74.
75.
Ordering Recommendation:  

Detect and quantify hepatitis B virus.

76.
Ordering Recommendation:  

Determine exposure to HBV infection. May be helpful in determining which patients are at risk for HBV reactivation and would benefit from prophylactic nucleoside analog treatment prior to initiation of immunosuppression therapy.

77.
Ordering Recommendation:  

Can be ordered as part of the acute hepatitis panel which includes HAV IgM, HBV core antibody IgM, HBV surface antigen, and HCV antibody to determine if patient has acute HBV infection. Refer to Hepatitis Panel, Acute with Reflex to HBsAg Confirmation (0020457).

78.
Ordering Recommendation:  

Determine antiviral drug resistance by DNA sequencing.

79.
Ordering Recommendation:  

Indicates stage of infection. Use to monitor patients with chronic hepatitis B infection and known positive Hepatitis B surface antigen.

80.
Ordering Recommendation:  

Monitor post-liver-transplant therapy with hepatitis B immunoglobulin in HBV-positive patients and ascertain response to HBV vaccines.

81.
Ordering Recommendation:  

Order for confirmation of HBV in pregnant women (prenatal testing).

82.
Ordering Recommendation:  

Can be ordered as part of the acute hepatitis panel which includes HAV IgM, HBV core antibody IgM, HBV surface antigen, and HCV antibody. Refer to Hepatitis Panel, Acute with Reflex to HBsAg Confirmation (0020457).

83.
Ordering Recommendation:  

Order for HBV screening in pregnant women (prenatal testing).

84.
Ordering Recommendation:  

Detect acute or chronic HBV infection.

85.
Ordering Recommendation:  

Monitor HBV therapy; order along with HBV DNA, HBV surface antigen, HBV surface antibody and HBe antigen.

86.
Ordering Recommendation:  

Monitor HBV therapy; order along with HBV DNA, HBV surface antigen, HBV surface antibody and HBe antibody.

87.
Ordering Recommendation:  

Monitor confirmed chronic hepatitis B infection.

88.
Ordering Recommendation:  

Preferred reflex test to confirm active HCV infection following positive HCV screen. Reflex to genotype aids in prognosis and treatment selection.

89.
Ordering Recommendation:  

Confirm active HCV infection following positive HCV screen when a higher level of subtype resolution is required.

90.
Ordering Recommendation:  

Reflex genotyping panel for prognosis and treatment selection when a higher level of subtype resolution is required. Do not order prior to molecular confirmation of positive HCV screen.

91.
Ordering Recommendation:  

Recommended testing for HCV genotype 1 patients prior to initiating simeprevir therapy.

92.
Ordering Recommendation:  

Order before initiating treatment with NS5A inhibitors. Do not order prior to molecular confirmation of positive hepatitis C virus (HCV) screen and confirmation of genotype 1a or 1b.

93.
Ordering Recommendation:  

Preferred single screening test for:
• One time screening of population born between 1945-1965
• Individuals at risk for HCV
Positive results require confirmation by molecular testing (eg, Hepatitis C Virus by Quantitative PCR (0098268) or Hepatitis C Virus (HCV) by Quantitative PCR with Reflex to HCV Genotype by Sequencing (2002685)).

94.
Ordering Recommendation:  

Preferred reflex test for screening and confirming HCV in at-risk individuals. If positive, reflexes to quantitative HCV PCR to confirm HCV infection.

95.
Ordering Recommendation:  

Preferred single test to confirm hepatitis C virus (HCV) infection following positive HCV screen.

96.
Ordering Recommendation:  

Preferred genotyping test for prognosis and selection. Do not order prior to molecular confirmation of positive hepatitis C virus (HCV) screen. Assay does not differentiate between type 1a and type 1b.

97.
Ordering Recommendation:  

Order before initiating hepatitis C virus (HCV) therapy to aid in prognisos and therapy selection when a higher level of subtype resolution is required (ie, non 6a/b vs. type 1 and type 1a vs. 1b). Do not order prior to molecular confirmation of positive HCV screen. 

98.
Ordering Recommendation:  

Diagnose HDV infection in patient with documented acute or chronic HBV and at risk for HDV infection. Consider ordering HBV core IgM antibody to determine whether HDV infection is a coinfection or a superinfection with HBV.

99.
Ordering Recommendation:  

Determine whether HDV infection is acute rather than chronic. Consider ordering  HBV IgM  core antibody to determine whether HDV infection is a coinfection or a superinfection with HBV.

100.
Ordering Recommendation:  

Diagnose HDV infection in patient with documented acute or chronic HBV and at risk for HDV infection. Consider ordering HBV IgM core antibody testing to determine whether HDV infection is a coinfection or a superinfection with HBV.

101.
Ordering Recommendation:  

Confirm and quantify the presence of hepatitis D virus.

102.
Ordering Recommendation:  

Stand-alone antibody testing is recommended. Refer to Hepatitis E Virus (HEV) Antibody, IgM (2010156) for acute disease or Hepatitis E Virus (HEV) Antibody, IgG (2010151) for exposure evaluation.

103.
Ordering Recommendation:  

Recommended for determining exposure to HEV.

104.
Ordering Recommendation:  

Preferred test for diagnosing acute HEV infection.

105.
Ordering Recommendation:  

Confirm and quantify the presence of hepatitis E virus.

106.
Ordering Recommendation:  

Order to evaluate viral etiology in patients with acute hepatitis. Not recommended for screening asymptomatic patients. Panel includes HAV IgM, HBV core antibody IgM, HBV surface antigen, HCV antibody.

107.
Ordering Recommendation:  

Acceptable panel for surveillance and monitoring of hepatocellular carcinoma.

108.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

109.
110.
Ordering Recommendation:  

Confirm etiology of hemolytic anemia in individuals with hemolysis or a family history of hemolytic anemia.

111.
Ordering Recommendation:  

This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.

112.
Ordering Recommendation:  

Alternate test when clinical/family history is classic for HHT, but this test does not detect large duplications/deletions.

113.
Ordering Recommendation:  

Acceptable test when clinical/family history is classic for HHT.

114.
Ordering Recommendation:  

Appropriate test when clinical/family history is classic for HHT.

115.
Ordering Recommendation:  

Most comprehensive test to determine the cause of a telangiectasia/AVM disorder.

116.
Ordering Recommendation:  

Appropriate test to confirm a clinical diagnosis of a HHT. Consider in particular when a telangiectasia/AVM syndrome is suspected but symptoms are not classic for HHT.

117.
Ordering Recommendation:  

Confirm a suspected diagnosis of hereditary paraganglioma-pheochromocytoma when SDHB, SDHC, and SDHD gene testing is negative.

118.
Ordering Recommendation:  

Use when SDHB-related hereditary paraganglioma-pheochromocytoma is suspected.

119.
Ordering Recommendation:  

This is a second tier test and REQUIRES PERMISSION from  ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.

120.
Ordering Recommendation:  

Preferred initial test when hereditary paraganglioma-pheochromocytoma is suspected.

121.
Ordering Recommendation:  

Use when SDHC-related hereditary paraganglioma-pheochromocytoma is suspected.

122.
Ordering Recommendation:  

Use when SDHD-related hereditary paraganglioma-pheochromocytoma is suspected.

123.
Ordering Recommendation:  

Aid in determining the cause of elevated hemoglobin F. Confirm suspected deletional HPFH. Carrier testing for individuals with a family history consistent with HPFH.

124.
125.
126.
Ordering Recommendation:  

• Assess and monitor patient with possible pemphigoid gestationis (herpes gestationis).
• Pemphigoid gestationis is a rare disease of pregnancy; consider other types of immunobullous disease testing, (i.e., Epithelial Basement Membrane Zone Antibody IgA (0092057), Collagen Type VII Antibody IgG by ELISA (2010905), and/or Pemphigus Antibody Panel - Epithelial Cell Surface Antibodies and Desmoglein 1 and Desmoglein 3 Antibodies, IgG (0090650)).

127.
Ordering Recommendation:  

In the absence of active lesions, this is the preferred serology test for diagnosing herpes simplex viral infection.

128.
Ordering Recommendation:  

Detect and genotype herpes simplex virus (HSV) types 1 and 2.

129.
Ordering Recommendation:  

Differentiate herpes simplex virus (HSV) types 1 and 2 based on cultured virus isolates. For culture combined with typing, refer to Herpes Simplex Virus Culture with Reflex to HSV Typing (0065065).

130.
Ordering Recommendation:  

Genotype herpes simplex virus (HSV) types 1 and 2.

131.
Ordering Recommendation:  

Preferred test for detecting herpes simplex virus (HSV) infection in CSF, neonates, or when rapid diagnostic test for suspected HSV infection is necessary.

132.
Ordering Recommendation:  

Traditional gold standard test for identifying acute herpes simplex virus (HSV) infection in active lesions (eg, vesicles, ulcers, inflamed mucous membranes). Molecular testing is generally preferred (refer to Herpes Simplex Virus by PCR (0060041)).

133.
Ordering Recommendation:  

Detect herpes simplex virus (HSV) by viral culture and differentiate types 1 and 2. Molecular testing is generally preferred (refer to Herpes Simplex Virus by PCR (0060041)).

134.
Ordering Recommendation:  

A rapid diagnostic test with culture backup for negative DFA results. Test may be helpful in identifying acute herpes simplex virus (HSV) infection in active lesions (eg, vesicles, ulcers, inflammation of mucous membranes). Molecular testing is generally preferred (refer to Herpes Simplex Virus by PCR (0060041)).

135.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

136.
Ordering Recommendation:  

Not recommended as a stand-alone test. Refer to Herpes Simplex Virus Type 1 and/or 2 Antibodies, IgG with Reflex to Type 1 and 2 Glycoprotein G-Specific Ab, IgG (0051708).

137.
Ordering Recommendation:  

Not recommended for herpes simplex virus (HSV) testing; lacks adequate predictive value for acute infection. Preferred testing is Herpes Simplex Virus by PCR (0060041).

138.
Ordering Recommendation:  

Not recommended for herpes simplex virus (HSV) testing; IgM lacks adequate predictive value for acute infection. If pursuing antibody testing, preferred test is Herpes Simplex Type 1 and Type 2 Glycoprotein G-Specific Antibodies, IgG by CIA (0051152). If acute HSV infection is suspected, molecular testing is preferred (refer to Herpes Simplex Virus by PCR​ (0060041)).

139.
Ordering Recommendation:  

Not recommended for herpes simplex virus (HSV) testing; IgM lacks adequate predictive value for acute infection. If pursing antibody testing, refer to Herpes Simplex Type 1 and Type 2 Glycoprotein G-Specific Antibodies, IgG by CIA (0051152). If acute HSV infection is suspected, molecular testing is preferred (refer to Herpes Simplex Virus by PCR (0060041)).

140.
Ordering Recommendation:  

Preferred testing for herpes simplex virus (HSV) when recent acquisition of herpes simplex virus is suspected. Because glycoprotein antibodies may require 3-6 months to form, follow-up testing is recommended to confirm a negative IgG glycoprotein result in the context of positive HSV types 1 or 2 antibody results. Refer to Herpes Simplex Type 1 and Type 2 Glycoprotein G-Specific Antibodies, IgG by CIA (0051152).

141.
Ordering Recommendation:  

For suspected and/or active herpes simplex virus (HSV) infection, molecular testing is preferred (refer to Herpes Simplex Virus by PCR (0060041)). If pursuing antibody testing, refer to Herpes Simplex Virus Type 1 Glycoprotein G-Specific Antibody, IgG by ELISA, CSF (0050379) and Herpes Simplex Virus Type 2 Glycoprotein G-Specific Antibody, IgG by ELISA, CSF (0050359). If acute HSV infection is suspected, molecular testing is preferred (refer to Herpes Simplex Virus by PCR (0060041)).

142.
Ordering Recommendation:  

Not recommended for herpes simplex virus (HSV) testing; IgM lacks adequate predictive value for acute infection. If pursuing antibody testing, refer to Herpes Simplex Type 1 and Type 2 Glycoprotein G-Specific Antibodies, IgG by CIA (0051152). If acute HSV infection is suspected, molecular testing is preferred (refer to Herpes Simplex Virus by PCR (0060041)).

143.
Ordering Recommendation:  

Not recommended for herpes simplex virus (HSV) testing; IgM lacks adequate predictive value for acute infection. Molecular testing is preferred (refer to Herpes Simplex Virus by PCR (0060041)).

144.
Ordering Recommendation:  

Not a stand-alone test. Order in conjunction with Herpes Simplex Virus Type 2 Glycoprotein G-Specific Antibody, IgG by CIA (0050294). Because glycoprotein antibodies may require 3-6 months to form, follow-up testing is recommended to confirm a negative IgG glycoprotein result in the context of positive HSV Types 1 or 2 antibody results.

145.
Ordering Recommendation:  

Not a stand-alone test. Molecular testing is preferred (refer to Herpes Simplex Virus by PCR (0060041)).

146.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

147.
Ordering Recommendation:  

Not a first-line test for herpes simplex virus (HSV) 2 typing.

148.
Ordering Recommendation:  

Not a stand-alone test. Order in conjunction with Herpes Simplex Virus Type 1 Glycoprotein G-Specific Antibody, IgG by CIA (0050292).

149.
Ordering Recommendation:  

Not a stand-alone test. Molecular testing is preferred (refer to Herpes Simplex Virus by PCR (0060041)).

150.
151.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

152.
Ordering Recommendation:  

Can be used in conjunction with Herpesvirus 6 Antibody, IgM Screen with Reflex to Titer by IFA (2011420) for diagnosis of HHV-6 disease in immunocompromised adults. Consider Human Herpesvirus 6 (HHV-6A and HHV-6B) by Quantitative PCR (0060071) as an alternative, especially in cases of suspected meningitis.

153.
Ordering Recommendation:  

Can be used in conjunction with Herpesvirus 6 Antibody, IgG (2013423) for diagnosis of HHV-6 disease in immunocompromised adults. Consider Human Herpesvirus 6 (HHV-6A and HHV-6B) by Quantitative PCR (0060071) as an alternative, especially in cases of suspected meningitis.

154.
Ordering Recommendation:  

May be used as an initial serologic test to detect acute Epstein-Barr virus infectious mononucleosis.

155.
Ordering Recommendation:  

Preferred initial serologic test to detect acute Epstein-Barr virus infectious mononucleosis.

156.
Ordering Recommendation:  

Preferred test is Lupus Anticoagulant Reflexive Panel (0030181).

157.
Ordering Recommendation:  

Preferred initial test to diagnose suspected Tay-Sachs disease or identify carriers of Tay-Sachs disease. Use for individuals who are pregnant, use oral contraceptives, have severe liver or autoimmune disease, or had previously inconclusive HEX A enzyme serum/plasma level. Can detect Sandhoff disease.

158.
Ordering Recommendation:  

Diagnose suspected Tay-Sachs disease or identify carriers of Tay-Sachs disease in males and nonpregnant females. For individuals who are pregnant, use oral contraceptives, have severe liver or autoimmune disease, or had previously inconclusive HEX A enzyme serum/plasma level, the preferred test is Hexosaminidase A percent and Total Hexosaminidase in Leukocytes (2008125). Can detect Sandhoff disease.

159.
Ordering Recommendation:  

Diagnose suspected Tay-Sachs disease or identify carriers of Tay-Sachs disease in males and nonpregnant females. For individuals who are pregnant, use oral contraceptives, or have severe liver or autoimmune disease, the preferred test is Hexosaminidase A percent and Total Hexosaminidase in Leukocytes (2008125). Can detect Sandhoff disease.

160.
Ordering Recommendation:  

Evaluate the cause of an isolated prolonged PTT in a patient who is not currently bleeding.

161.
Ordering Recommendation:  

Acceptable initial test when antiphospholipid syndrome (APS) is strongly suspected. More specific than cardiolipin IgG and IgM antibodies in the diagnosis of APS.

162.
Ordering Recommendation:  

Aids in the detection and subclassification of hyperandrogenism. Most useful in women and children with moderate/severe hirsutism or hirsutism of any degree when it is sudden in onset or rapidly progressive.

163.
Ordering Recommendation:  

Aid in evaluation of patient with allergic signs and symptoms, such as anaphylaxis; may assist in diagnosing and monitoring of mast-cell activation disorders.

164.
Ordering Recommendation:  

Aid in evaluation of patient with allergic signs and symptoms, such as anaphylaxis. May assist when diagnosing and monitoring mast-cell activation disorders or when evaluating histamine production over a longer time frame.

165.
Ordering Recommendation:  

Aid in evaluation of patient with allergic signs and symptoms, such as anaphylaxis; may assist in diagnosing and monitoring of mast-cell activation disorders.

166.
Ordering Recommendation:  

Evaluate suspected drug-induced lupus. Negative results do not rule out drug-induced lupus.

167.
Ordering Recommendation:  

Not recommended as a stand-alone test. Refer to Histoplasma Antibodies by CF & ID (0050627).

168.
Ordering Recommendation:  

Aid in the diagnosis of histoplasmosis. Recommend testing in conjunction with Histoplasma Antigen by EIA, Serum (0092522) and Histoplasma Galactomannan Antigen Quantitative by EIA, Urine (2009418).

169.
Ordering Recommendation:  

Aid in the diagnosis of histoplasmosis. Recommend testing in conjunction with Histoplasma Antibodies by CF & ID (0050627) and Histoplasma Galactomannan Antigen Quantitative by EIA, Urine (2009418).

170.
Ordering Recommendation:  

Rapid test for identifying H. capsulatum (yeast or mold form) from a pure isolate.

171.
Ordering Recommendation:  

Aid in the diagnosis of histoplasmosis. Recommend testing in conjunction with Histoplasma Antibodies by CF & ID (0050627) and Histoplasma Antigen by EIA, Serum (0092522).

172.
Ordering Recommendation:  

Not recommended as a stand-alone test. Refer to Histoplasma Antibodies by CF & ID (0050627).

173.
174.
Ordering Recommendation:  

HIV-1 combined pheno- and genotyping provides antiretroviral susceptibility information for protease inhibitors (PI)
and reverse transcriptase inhibitors (NRTI, NNRTI). Useful in clarifying and confirming results from HIV genotyping tests. Intended for patients with viral load >500 copies/mL.

175.
Ordering Recommendation:  

HIV-1 sequencing test identifies tropism (CCR5 or CXCR4) of HIV-1 virus in patients being considered for CCR5 or CSCR4 antagonist therapy. If patients viral load is <1,000 HIV-1 copies/mL, refer to Trofile DNA Co-Receptor Tropism Assay (2004747).

176.
Ordering Recommendation:  

HIV-1 deep sequencing test predicts susceptibility to
• Protease inhibitors (PI)
• Reverse transcriptase inhibitors (NRTI, NNRTI)
• Integrase inhibitors (INI)
• Receptor inhibitors (CCR5 or CXCR4 tropism)

Some studies have shown improved outcomes using deep versus traditional (Sanger) HIV sequencing, but other studies have not.
• 2014 European case-control study for NNRTIs (refer to PubMed ID: 25336166)
• 2015 French study on highly-pretreated patients (refer to PubMed ID: 25755001)
• 2016 Uganda retrospective study on antiviral treatment failures (refer to PubMed ID: 27001818) 

177.
Ordering Recommendation:  

HIV genotyping provides susceptibility information for ntegrase inhibitors (INI). Intended for patients with viral load >500 copies/mL.

178.
Ordering Recommendation:  

HIV-1 genotyping provides antiretroviral susceptibility information for protease inhibitors (PI), reverse transcriptase inhibitors (NRTI, NNRTI), and integrase inhibitors. Intended for patients with viral load >1000 copies/mL.

179.
180.
Ordering Recommendation:  

Test is intended for pre-transplant allele matching. Do not use for specific disease screening or diagnosis (eg, celiac disease, rheumatologic diseases).

181.
Ordering Recommendation:  

Test is not intended for HLA-related disease screening or diagnosis (eg, celiac disease, narcolepsy, rheumatologic diseases).

182.
Ordering Recommendation:  

May be useful in immunization/vaccination trials or may aid in the clinical diagnosis of diseases strongly associated with the HLA-DRB 3*, 4*, 5* loci.

183.
Ordering Recommendation:  

The intended use of this test is pre-transplant allele matching. Do not use for HLA-related disease screening or diagnosis (eg, celiac disease, narcolepsy, rheumatologic diseases).

184.
Ordering Recommendation:  

May be useful in immunization/vaccination trials or may aid in the clinical diagnosis of diseases strongly associated with the HLA-A locus.

185.
Ordering Recommendation:  

The intended use of this test is pre-transplant allele matching. Do not use for HLA-related disease screening or diagnosis (eg, celiac disease, narcolepsy, rheumatologic diseases).

186.
Ordering Recommendation:  

May be useful in immunization/vaccination trials or may aid in the clinical diagnosis of diseases strongly associated with the HLA-B locus.

187.
Ordering Recommendation:  

Identify patients prior to treatment with carbamazepine (CBZ) who may be at risk for developing Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Recommended for patients not currently taking carbamazepine.

188.
Ordering Recommendation:  

Standard of care prior to abacavir therapy per FDA. Predict risk of abacavir hypersensitivity syndrome. Relevant to most populations.

189.
Ordering Recommendation:  

May assist in the diagnosis of ankylosing spondylitis, juvenile rheumatoid arthritis, and Reiter's syndrome. This test is not diagnostic for these disorders and should be correlated with other clinical signs and symptoms. Flow cytometry is the preferred test for most patients since its sensitivity and specificity are nearly equivalent to Ankylosing Spondylitis (HLA-B27) Genotyping (0050392).

190.
Ordering Recommendation:  

The intended use of this test is pre-transplant allele matching. Do not use for HLA-related disease screening or diagnosis (eg, celiac disease, narcolepsy, rheumatologic diseases).

191.
Ordering Recommendation:  

May be useful in immunization/vaccination trials or may aid in the clinical diagnosis of diseases strongly associated with the HLA-C locus.

192.
Ordering Recommendation:  

May be useful in immunization/vaccination trials or may aid in the clinical diagnosis of diseases strongly associated with the HLA-DP locus.

193.
Ordering Recommendation:  

The intended use of this test is pre-transplant allele matching. Do not use for HLA-related disease screening or diagnosis (eg, celiac disease, narcolepsy, rheumatologic diseases).

194.
Ordering Recommendation:  

May be useful in immunization/vaccination trials or may aid in the clinical diagnosis of diseases strongly associated with the HLA-DQ locus. To rule out celiac disease (when other testing is inconclusive), refer to Celiac Disease (HLA-DQ2 and HLA-DQ8) Genotyping (2005018). When narcolepsy is suspected in symptomatic individuals, refer to Narcolepsy (HLA-DQB1*06:02) Genotyping (2005023).

195.
Ordering Recommendation:  

The intended use of this test is pre-transplant allele matching. Do not use for HLA-related disease screening or diagnosis (eg, celiac disease, narcolepsy, rheumatologic diseases).

196.
Ordering Recommendation:  

Do not use for specific disease screening or diagnosis (eg , celiac disease, rheumatologic diseases).

197.
Ordering Recommendation:  

The intended use of this test is pre-transplant allele matching. Do not use for HLA-related disease screening or diagnosis (eg, celiac disease, narcolepsy, rheumatologic diseases).

198.
Ordering Recommendation:  

Detect germline MLH1 variants. Use in MMR-deficient carcinoma with suggestive IHC (loss of MLH1 and PMS2 proteins), absence of BRAF codon 600 variant, and normal MLH1 methylation studies.

199.
Ordering Recommendation:  

Detect germline MSH2 variants. Use in MMR-deficient carcinoma with suggestive IHC (loss of MSH2 and MSH6 proteins).

200.
Ordering Recommendation:  

Detect germline MSH6 variants. Use in MMR-deficient carcinoma with suggestive IHC (isolated loss of MSH6 protein).

201.
Ordering Recommendation:  

Detect germline PMS2 variants. Use in MMR-deficient carcinoma with suggestive IHC (isolated loss of PMS2 protein).

202.
Ordering Recommendation:  

This is a second tier test and REQUIRES PERMISSION from  ARUP's Genetic Counselor (800-242-2787, x2141) before ordering.

203.
Ordering Recommendation:  

Preferred test for individual with clinical phenotype of HPE and a normal karyotype.

204.
Ordering Recommendation:  

Preferred test for fetuses with HPE that is not caused by a structural or numerical chromosome abnormality.

205.
Ordering Recommendation:  

Acceptable test for individual with clinical phenotype of HPE and a normal karyotype. Preferred test is Holoprosencephaly Panel, Nonsyndromic, Sequencing and Deletion/Duplication, 11 Genes (2008848).

206.
Ordering Recommendation:  

This is a second tier test and REQUIRES PERMISSION from  ARUP's Genetic Counselor (800-242-2787, x2141) before ordering.  Preferred initial test is the sequencing and deletion/duplication test.

207.
Ordering Recommendation:  

Acceptable screening test for disorders of methionine metabolism (congenital hyperhomocysteinemia). Not recommended for risk assessment of cardiovascular disease or venous thromboembolism.

208.
Ordering Recommendation:  

Monitor patients with homocystinuria.

209.
Ordering Recommendation:  

Initial test for the diagnosis and monitoring of neuroblastoma; order concurrently with Vanillylmandelic Acid (VMA), Urine (0080421).

210.
Ordering Recommendation:  

Detects HRAS mutations (codons 12, 13, 61) associated with thyroid cancer.

211.
212.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

213.
Ordering Recommendation:  

Use with CA 125 to monitor ovarian cancer, usually epithelial subtype, post therapy if pretreatment level was elevated. Not recommended for monitoring known mucinous or germ cell ovarian cancer. Not a stand-alone test for ovarian cancer screening or diagnosis.

214.
Ordering Recommendation:  

Detect and quantify HHV6 subtypes A and B in immunocompromised patients.

215.
Ordering Recommendation:  

Detect and quantify herpesvirus 8 (HHV-8).

216.
Ordering Recommendation:  

2014 CDC Recommended Algorithm for Laboratory Diagnosis of HIV infection. This 4th generation test screens for HIV-1 p24 antigen and antibodies to HIV-1 (groups M and O) and HIV-2. Repeatedly reactive HIV-1, 2 antigen/antibody screening results are confirmed with an HIV-1/ HIV-2 antibody differentiation test. Negative or indeterminate results for HIV-1/2 antibody differentiation are confirmed with a quantitative PCR test.

217.
218.
Ordering Recommendation:  

• This 4th generation test screens for HIV-1 p24 antigen and antibodies to HIV-1 (groups M and O) and HIV-2. Repeatedly reactive HIV-1, 2 antigen/antibody screening results will reflex to an HIV-1/HIV-2 antibody differentiation test.
•This test does not complete the 2014 CDC Recommended Algorithm for Laboratory Diagnosis of HIV Infection. Preferred test is Human Immunodeficiency Virus (HIV) Combo Antigen/Antibody (HIV-1/O/2) by ELISA, Reflexive Panel (2012674).

219.
Ordering Recommendation:  

HIV-1 phenotyping provides antiretroviral susceptibility information for protease inhibitors (PI) and reverse transcriptase inhibitors (NRTI, NNRTI). Intended for patients with viral load >500 copies/mL.

220.
Ordering Recommendation:  

Detect HIV-1 RNA and proviral DNA.

221.
Ordering Recommendation:  

Detect and quantify HIV-1; includes phenotypic determination.

222.
Ordering Recommendation:  

Detect and quantify HIV-1. Determine HIV drug resistance by DNA sequencing.

223.
Ordering Recommendation:  

Detect and quantify HIV-1.

224.
Ordering Recommendation:  

HIV-1 genotyping provides antiretroviral susceptibility information for protease inhibitors (PI) and reverse transcriptase inhibitors (NRTI, NNRTI). Intended for patients with viral load >1,000 copies/mL.

225.
226.
Ordering Recommendation:  

Order this assay only when a specimen is repeatedly reactive for HIV-1 or HIV 1-2 antibodies.

227.
Ordering Recommendation:  

Order only if patient is positive (repeatedly reactive) for combined HIV-1 and HIV-2 antibody screen.

228.
Ordering Recommendation:  

HIV genotyping to detect resistance in HIV-1 to antiretroviral drugs. Preferred test is HIV1 Genotype and Integrase Inhibitor Resistance by Sequencing (2009256).

229.
Ordering Recommendation:  

HIV-1 combined pheno- and genotyping test provides antiretroviral susceptibility information for protease inhibitors (PI), reverse transcriptase inhibitors (NRTI, NNRTI), and integrase inhibitors (INI). Preferred test for patients with known or suspected complex drug resistance patterns (eg, suboptimal virologic response to treatment and viral load rebound).

230.
231.
232.
Ordering Recommendation:  

Use only when patient has a repeatedly reactive third- or fourth-generation HIV screen test result. This test discriminates between HIV-1 and HIV-2 antibodies. 

233.
Ordering Recommendation:  

Useful as a supplemental assay for repeatedly reactive third- or fourth-generation HIV screen tests, when following the CDC Proposed HIV Diagnostic Algorithm. This test cannot be used as a rapid screen nor as a follow-up for a positive rapid screen.

234.
Ordering Recommendation:  

Order to detect human metapneumovirus (hMPV) in children and immunocompromised adults if suspicion remains in spite of negative hMPV DFA test.

235.
Ordering Recommendation:  

Preferred initial test to detect human metapneumovirus (hMPV) in children and adults.

236.
Ordering Recommendation:  

Use of FDA-cleared sample preservative (ie, ThinPrep) is recommended. Refer to Human Papillomavirus (HPV), High Risk with 16 and 18 Genotype by PCR, ThinPrep (2011940).

237.
Ordering Recommendation:  

FDA-approved test for triaging women ≥30 years with negative cervical cytology (NILM Pap smear) and positive HPV test.

238.
Ordering Recommendation:  

Detects low-risk HPV subtypes 6 and 11. Preferred in situ hybridization test to determine potential cancer risk is Human Papillomavirus (HPV), High Risk by in situ Hybridization, Paraffin (2002899).

239.
Ordering Recommendation:  

FDA-approved test for routine cervical cancer screening in combination with cervical cytology (Pap smear) in women 30 years. Follow-up test for abnormal cytology results in women ≥21 years.

240.
Ordering Recommendation:  

FDA-approved test for routine cervical cancer screening in combination with cervical cytology (Pap smear) in women ≥30 years. Follow-up test for abnormal cytology results in women ≥21 years.
Other ThinPrep testing options include Human Papillomavirus (HPV), High Risk by Transcription-Mediated Amplification (TMA), ThinPrep (2007893), Human Papillomavirus (HPV), High Risk by Transcription-Mediated Amplification (TMA), ThinPrep (2011947), and Human Papillomavirus (HPV), High Risk with 16 and 18 Genotype by PCR, ThinPrep (2011940).

241.
Ordering Recommendation:  

Preferred in situ hybridization test detects high-risk HPV subtypes 16 and 18 to determine potential cancer risk.

242.
Ordering Recommendation:  

FDA-approved test for routine cervical cancer screening in combination with cervical cytology (Pap smear) for women ≥30 years. Follow-up test for abnormal cytology results in women ≥21 years.

243.
Ordering Recommendation:  

FDA-approved test for routine cervical cancer screening in combination with cervical cytology (Pap smear) for women ≥30 years. Follow-up test for abnormal cytology results in women ≥21 years. 

244.
Ordering Recommendation:  

FDA-approved test for routine cervical cancer screening in combination with cervical cytology (Pap smear) in women ≥30 years; genotyping performed for triaging women to colposcopy who are cytology-negative (NILM) and HPV-positive.

245.
Ordering Recommendation:  

FDA-approved test for routine cervical cancer screening in combination with cervical cytology (Pap smear) in women ≥30 years. Follow-up test for abnormal cytology results in women ≥21 years.

246.
Ordering Recommendation:  

FDA-approved test for routine cervical cancer screening in combination with cervical cytology (Pap smear) for women ≥30 years. Follow-up test for abnormal cytology results in women ≥21 years.

247.
Ordering Recommendation:  

FDA-approved platform for primary HPV screening in women ≥25 years. FDA-approved test for routine cervical cancer screening in combination with cervical cytology (Pap smear) in women ≥30 years. Follow-up test for abnormal cytology results in women ≥21 years.

248.
249.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

250.
251.
Ordering Recommendation:  

Confirm antibody test results for a positive screening test (HTLV types I and II).

252.
253.
254.
255.
Ordering Recommendation:  

Evaluate patients with recurrent and chronic infections.

256.
Ordering Recommendation:  

Diagnostic confirmation for Huntington disease (HD) in a symptomatic individual. Presymptomatic testing for adults with a family history of HD.

257.
Ordering Recommendation:  

Noninvasive assessment of liver status.

258.
259.
260.
261.
Ordering Recommendation:  

Preferred test for individuals with clinical phenotype of hyper IgM syndrome.

262.
263.
Ordering Recommendation:  

Evaluate patients suspected of having hypersensitivity pneumonitis induced by exposure to Aspergillus fumigatus, Thermoactinomyces vulgaris, Aurebasidium pullulans, or Micropolyspora faeni.

264.
Ordering Recommendation:  

Evaluate patients suspected of having hypersensitivity pneumonitis induced by exposure to Aspergillus flavus, Aspergillus fumigatus, Saccharomonospora viridis, Thermoactinomyces candidus, and Thermoactinomyces sacchari.

265.
Ordering Recommendation:  

Confirms a diagnosis of hypochondroplasia in individuals with clinical or radiological evidence of the condition.

266.
Ordering Recommendation:  

Preferred test for evaluating if etiology of hypoglycemia is sulfonylurea ingestion.

267.
Ordering Recommendation:  

This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.

268.
Ordering Recommendation:  

Recommended test for confirming a diagnosis of hypohydrotic ectodermal dysplasia.

269.
Ordering Recommendation:  

Detects the majority of causative hypohydrotic ectodermal dysplasia variants, but will not detect rare large deletions or duplications.